Scinus Cell Expansion Announces Rebranding of SCINUS bioreactor NG to Osilaris™
PRESS RELEASE
Zeist, The Netherlands, September 2025
Scinus Cell Expansion, a leader in scalable bioreactor solutions for cell therapy manufacturing, today announced the rebranding of its flagship SCINUS bioreactor NG. Moving forward, the system will be known as Osilaris™, a name that reflects both the technical innovation and dynamic movement at the heart of the technology.
The decision to rebrand was driven by the need to create a clear distinction between the company name and its bioreactor platform. “We noticed that having the company and the bioreactor share the same name sometimes led to confusion,” said Erik Vossenaar (Managing Director) at Scinus Cell Expansion. “By introducing Osilaris™, we create a stronger, more distinct brand identity while staying true to our heritage.”
The new name Osilaris™ draws inspiration from the oscillatory motion of the rocker system, which is essential for optimal mixing and gas transfer within the bioreactor.
“Osilaris™ embodies a fusion of dynamic innovation and technical excellence,” said Rens Roosloot (Technology Manager). “It captures the movement inherent in our system while providing a versatile brand platform for future product lines.”
As part of the rebranding, Scinus Cell Expansion has also launched a redesigned website. The new site reflects the updated brand identity and provides visitors with streamlined access to product information, resources, and company updates. This rebranding also extends to current and future Scinus’ consumables and ancillary products and technologies.
The transition to Osilaris™ reflects Scinus Cell Expansion’s ongoing commitment to making cell therapy manufacturing smarter, more scalable, and more accessible worldwide.
-END-
More information:
Scinus Cell Expansion Netherlands B.V.
Utrechtseweg 48, 3704 HE, Zeist, The Netherlands
www.scinus.com | info@scinus.com
About Scinus Cell Expansion:
Scinus Cell Expansion develops technologies and services that advance cell therapy and regenerative medicine. Our mission is to help make cell therapies accessible to patients worldwide. We are commercializing Osilaris™, a closed, GMP-compliant bioreactor system for stem cell cultivation. Osilaris™ provides a cost-effective, controlled alternative to conventional production, enabling expansion of adherent cells, suspension cells, and organoids within a single closed system. The system’s patented, single-use, volume-expandable culture bags allow large-scale expansion in a homogenized, low-shear environment—ideal for scaling out (stem) cell cultures. In addition, Scinus supports clients in translating cell culture processes into commercial-scale, GMP-compliant production strategies.
For more information, please visit our website www.scinus.com and follow us on LinkedIn